Please assess the completion status of the following clinical trial:

Trial Title: Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~1. A documented diagnosis of eosinophilic esophagitis (EoE)~2. Baseline endoscopic biopsies with a demonstration on central reading of intraepithelial eosinophilic infiltration~Key Exclusion Criteria:~1. Body weight \<5 kg or ≥60 kg at screening~2. Other causes of esophageal eosinophilia~3. Active Helicobacter pylori~4. History of Crohn's disease, ulcerative colitis, celiac disease, or prior esophageal surgery~5. Any esophageal stricture unable to be passed with a standard, diagnostic, upper endoscope or any critical esophageal stricture that requires dilation at screening~6. Treatment with swallowed topical corticosteroids within 8 weeks prior to baseline standard of care endoscopy~7. History of bleeding disorders or esophageal varices that, in the opinion of the investigator, would put the patient at undue risk for significant complications from an endoscopy procedure~8. Active parasitic infection or suspected parasitic infection~9. Known or suspected immunodeficiency disorder~Key Exclusion for Patients Re-Entering the Study (for Entry into Part C, as defined in protocol):~1. Patients who are ≥12 years old, weigh ≥40 kg (or minimum weight for which dupilumab is approved for EoE), and dupilumab is commercially available for the treatment of EoE in their country~2. Patients who, during their previous participation in this clinical trial, developed an SAE and/or AE deemed related to dupilumab, which in the opinion of the investigator or of the medical monitor could indicate that continued treatment with dupilumab may present an unreasonable risk for the patient~3. Patients who did not undergo endoscopy with biopsies at week 16 and/or week 52 or prior to receiving rescue treatment Note: If the endoscopy with biopsies could not occur due to COVID-19 restrictions and rescue treatment was needed to be initiated without delay, these patients will be eligible to participate in Part C~4. Patients who became pregnant during their previous participation in this dupilumab clinical trial~5. Patients who, during their previous participation in this trial, were prematurely withdrawn because of a protocol violation, poor compliance, or inability to complete required study assessments~NOTE: Other protocol defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Part A - High Dose (Type: EXPERIMENTAL): Part A consists of a 16-week double-blind treatment period. Patients will be randomized to receive dupilumab or placebo subcutaneous (SC) administration at tiered dosing regimens based on body weight
- Part A - Low Dose (Type: EXPERIMENTAL): Part A consists of a 16-week double-blind treatment period. Patients will be randomized to receive dupilumab or placebo subcutaneous (SC) administration at tiered dosing regimens based on body weight
- Part B - High Dose (Type: EXPERIMENTAL): Part B consists of a 36-week extended active treatment period. All patients to receive subcutaneous (SC) administration at tiered dosing regimens based on body weight
- Part B - Low Dose (Type: EXPERIMENTAL): Part B consists of a 36-week extended active treatment period. All patients to receive subcutaneous (SC) administration at tiered dosing regimens based on body weight
- Part C - High Dose (Type: EXPERIMENTAL): Part C consists of up to 108-week open-label extension period. All patients will receive higher exposure dupilumab subcutaneous (SC) administration at tiered dosing regimens based on body weight. No matching placebo administered in Part C.

Based on this trial design, predict the completion outcome and termination type (if applicable).